185 related articles for article (PubMed ID: 33354500)
1. Targeting human MutT homolog 1 (MTH1) for cancer eradication: current progress and perspectives.
Yin Y; Chen F
Acta Pharm Sin B; 2020 Dec; 10(12):2259-2271. PubMed ID: 33354500
[TBL] [Abstract][Full Text] [Related]
2. Targeting the nucleic acid oxidative damage repair enzyme MTH1: a promising therapeutic option.
Ding Y; Liu Q
Front Cell Dev Biol; 2024; 12():1334417. PubMed ID: 38357002
[TBL] [Abstract][Full Text] [Related]
3. A Double-Edged Sword: The Anti-Cancer Effects of Emodin by Inhibiting the Redox-Protective Protein MTH1 and Augmenting ROS in NSCLC.
Wahi D; Soni D; Grover A
J Cancer; 2021; 12(3):652-681. PubMed ID: 33403025
[No Abstract] [Full Text] [Related]
4. Association of MTH1 expression with the tumor malignant potential and poor prognosis in patients with resected lung cancer.
Fujishita T; Okamoto T; Akamine T; Takamori S; Takada K; Katsura M; Toyokawa G; Shoji F; Shimokawa M; Oda Y; Nakabeppu Y; Maehara Y
Lung Cancer; 2017 Jul; 109():52-57. PubMed ID: 28577950
[TBL] [Abstract][Full Text] [Related]
5. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
Abbas HHK; Alhamoudi KMH; Evans MD; Jones GDD; Foster SS
BMC Cancer; 2018 Apr; 18(1):423. PubMed ID: 29661172
[TBL] [Abstract][Full Text] [Related]
6. (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1.
Dai X; Guo G; Zou P; Cui R; Chen W; Chen X; Yin C; He W; Vinothkumar R; Yang F; Zhang X; Liang G
J Exp Clin Cancer Res; 2017 Sep; 36(1):120. PubMed ID: 28882182
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of MTH1 inhibition-induced DNA strand breaks: The slippery slope from the oxidized nucleotide pool to genotoxic damage.
Rai P; Sobol RW
DNA Repair (Amst); 2019 May; 77():18-26. PubMed ID: 30852368
[TBL] [Abstract][Full Text] [Related]
8. Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue.
McPherson LA; Troccoli CI; Ji D; Bowles AE; Gardiner ML; Mohsen MG; Nagathihalli NS; Nguyen DM; Robbins DJ; Merchant NB; Kool ET; Rai P; Ford JM
DNA Repair (Amst); 2019 Nov; 83():102644. PubMed ID: 31311767
[TBL] [Abstract][Full Text] [Related]
9. TH588, an MTH1 inhibitor, enhances phenethyl isothiocyanate-induced growth inhibition in pancreatic cancer cells.
Ikejiri F; Honma Y; Kasukabe T; Urano T; Suzumiya J
Oncol Lett; 2018 Mar; 15(3):3240-3244. PubMed ID: 29435064
[TBL] [Abstract][Full Text] [Related]
10. Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity.
Peng C; Li YH; Yu CW; Cheng ZH; Liu JR; Hsu JL; Hsin LW; Huang CT; Juan HF; Chern JW; Cheng YS
Bioorg Chem; 2021 May; 110():104813. PubMed ID: 33774493
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetics and structural biology of human MutT homolog, MTH1.
Nakabeppu Y
Mutat Res; 2001 Jun; 477(1-2):59-70. PubMed ID: 11376687
[TBL] [Abstract][Full Text] [Related]
12. MTH1 as a Chemotherapeutic Target: The Elephant in the Room.
Samaranayake GJ; Huynh M; Rai P
Cancers (Basel); 2017 May; 9(5):. PubMed ID: 28481306
[TBL] [Abstract][Full Text] [Related]
13. TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.
Moukengue B; Brown HK; Charrier C; Battaglia S; Baud'huin M; Quillard T; Pham TM; Pateras IS; Gorgoulis VG; Helleday T; Heymann D; Berglund UW; Ory B; Lamoureux F
EBioMedicine; 2020 Mar; 53():102704. PubMed ID: 32151797
[TBL] [Abstract][Full Text] [Related]
14. Validation and development of MTH1 inhibitors for treatment of cancer.
Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
[TBL] [Abstract][Full Text] [Related]
15. Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA-24 with Tumor-Selective Toxicity.
Kang N; Ma J; Hu Y; Di R; Wang L; Zhang X; Lai Y; Liu Y
Pharmaceuticals (Basel); 2024 Feb; 17(3):. PubMed ID: 38543077
[TBL] [Abstract][Full Text] [Related]
16. Expression and function of MutT homolog 1 in distinct subtypes of breast cancer.
Zhang X; Song W; Zhou Y; Mao F; Lin Y; Guan J; Sun Q
Oncol Lett; 2017 Apr; 13(4):2161-2168. PubMed ID: 28454376
[TBL] [Abstract][Full Text] [Related]
17. Farnesyl phenolic enantiomers as natural MTH1 inhibitors from
Gao Y; Zhu L; Guo J; Yuan T; Wang L; Li H; Chen L
Oncotarget; 2017 Nov; 8(56):95865-95879. PubMed ID: 29221173
[TBL] [Abstract][Full Text] [Related]
18. The Existence of MTH1-independent 8-oxodGTPase Activity in Cancer Cells as a Compensatory Mechanism against On-target Effects of MTH1 Inhibitors.
Samaranayake GJ; Troccoli CI; Zhang L; Huynh M; Jayaraj CJ; Ji D; McPherson L; Onishi Y; Nguyen DM; Robbins DJ; Karbaschi M; Cooke MS; Barrientos A; Kool ET; Rai P
Mol Cancer Ther; 2020 Feb; 19(2):432-446. PubMed ID: 31744893
[TBL] [Abstract][Full Text] [Related]
19. Birth of MTH1 as a therapeutic target for glioblastoma: MTH1 is indispensable for gliomatumorigenesis.
Tu Y; Wang Z; Wang X; Yang H; Zhang P; Johnson M; Liu N; Liu H; Jin W; Zhang Y; Cui D
Am J Transl Res; 2016; 8(6):2803-11. PubMed ID: 27398163
[TBL] [Abstract][Full Text] [Related]
20. Label-free target identification reveals oxidative DNA damage as the mechanism of a selective cytotoxic agent.
Park H; Park SB
Chem Sci; 2019 Mar; 10(12):3449-3458. PubMed ID: 30996934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
